Professional Documents
Culture Documents
Erwinanto MD
Department of Cardiology and Vascular Medicine
Division of Cardiovascular, Department of Internal Medicine
Faculty of Medicine Universitas Padjadjaran
Dr. Hasan Sadikin General Hospital
Bandung
PATIENTS NEED NEW
TREATMENT
Ponikowski P, et al. Eur Heart J 2016 doi:10.1093/eurheartj/ehw128
DOCTORS OFTEN SAY:
• My patient is “STABLE”
quality of life.
Am Heart J 2012;163:88-94
ACE-I 100%
Beta-blocker 93%
MRA 57%
69% NYHA II
25% NYHA III
1.0
ACE-I 100%
Cumulative probability
0.1
0.0
0 180 360 540 720 900 1080 1260
MEDICAL TREATMENT
Ponikowski P, et al. Eur Heart J 2016 doi:10.1093/eurheartj/ehw128
Ponikowski P, et al. Eur Heart J 2016 doi:10.1093/eurheartj/ehw128
Ponikowski P, et al. Eur Heart J 2016 doi:10.1093/eurheartj/ehw128
Ponikowski P, et al. Eur Heart J 2016 doi:10.1093/eurheartj/ehw128
Ponikowski P, et al. Eur Heart J 2016 doi:10.1093/eurheartj/ehw128
Ponikowski P, et al. Eur Heart J 2016 doi:10.1093/eurheartj/ehw128
BENEFITS OF ADDING
SACUBITRIL VALSARTAN
IMPORTANT GUIDANCE IN
SACUBITRIL VALSARTAN
1. Follow guideline directed treatment algorithm.
allowed.
• Have EF ≤35%
sarcubitril valsartan.